12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vibex MTX: Phase II data

An open-label Phase II trial in 101 patients with RA showed that single doses of 10-25 mg Vibex MTX were well tolerated with no serious adverse events reported. Additionally, patients experienced minimal...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >